Context: Cervavac, India’s first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for the prevention of cervical cancer has been developed.
About the new vaccine
- Cervavac was developed by the Pune-based Serum Institute of India in coordination with the Government of India’s Department of Biotechnology (DBT).
- HPV vaccines are given in two doses and the antibodies that develop after both are administered can last up to six or seven years.
- Unlike Covid vaccines, booster shots may not be required for the cervical cancer vaccine.
- Until now, the HPV vaccines available in India were produced by foreign manufacturers at an approximate cost of Rs 2,000 to Rs 3,500 per dose.
- Cervavac is likely to be significantly cheaper, slated to cost approximately Rs. 200 to 400.
- It has also demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
How common is cervical cancer in India?
- Despite being largely preventable, cervical cancer is the fourth most common cancer among women globally, according to the WHO.
- Current estimates indicate that every year approximately25 lakhs women are diagnosed with cervical cancer, and over 75 thousand dies from the disease in India, and 83 % of invasive cervical cancers are attributed to HPVs 16 or 18 in India, and 70% of cases worldwide.
- India accounts for about a fifth of the global burden of cervical cancer, with 1.23 lakh cases and around 67,000 deaths per year.
- Almost all cervical cancer cases are linked to certain strains of human papillomavirus (HPV), a common virus that is transmitted through sexual contact.
- While the body’s immune system usually gets rid of the HPV infection naturally within two years, in a small percentage of people the virus can linger over time and turn some normal cells into abnormal cells and then cancer.
Previous Year Question
Q1.) In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements:
- The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform.
- Sputnik V vaccine is manufactured using vector-based platform.
- COVAXIN is an inactivated pathogen-based vaccine.
Which of the statements given above are correct? (2022)
- 1 and 2 only
- 2 and 3 only
- 1 and 3 only
- 1, 2 and 3
Q.2) With reference to recent developments regarding ‘Recombinant vector Vaccines’, consider the following statements:
- Genetic engineering is applied in the development of these vaccines.
- Bacteria and viruses are used as vectors.
Which of the statements given above is/are correct? (2021)
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2